Benzodiazepine use in Sao Paulo, Brazil

Detalhes bibliográficos
Autor(a) principal: Campanha, Angela Maria
Data de Publicação: 2020
Outros Autores: Ravagnani, Beatriz, Milhoranc¸a, Igor André, Bernik, Márcio Antonini, Viana, Maria Carmen, Wang, Yuan-Pang, Andrade, Laura Helena
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Clinics
Texto Completo: https://www.revistas.usp.br/clinics/article/view/172921
Resumo: OBJECTIVES: To report the prevalence and factors associated with the use of benzodiazepines in the general population and those with a mental health condition in the metropolitan area of Sa˜o Paulo, Brazil. METHODS: 5,037 individuals from the Sao Paulo Megacity Mental Health Survey data were interviewed using the Composite International Diagnostic Interview, designed to generate DSM-IV diagnoses. Additionally, participants were asked if they had taken any medication in the previous 12 months for the treatment of any mental health condition. RESULTS: The prevalence of benzodiazepine use ranged from 3.6% in the general population to 7.8% among subjects with a mental health condition. Benzodiazepine use was more prevalent in subjects that had been diagnosed with a mood disorder as opposed to an anxiety disorder (14.7% vs. 8.1%, respectively). Subjects that had been diagnosed with a panic disorder (33.7%) or bipolar I/II (23.3%) reported the highest use. Individuals aged X50 years (11.1%), those with two or more disorders (11.2%), those with moderate or severe disorders (10%), and those that used psychiatric services (29.8%) also reported higher use. CONCLUSION: These findings give an overview of the use of benzodiazepines in the general population, which will be useful in the public health domain. Benzodiazepine use was higher in those with a mental health condition, with people that had a mood disorder being the most vulnerable. Furthermore, females and the elderly had high benzodiazepine use, so careful management in these groups is required.
id USP-19_3bb681cb08b969a649cecccf37d32efa
oai_identifier_str oai:revistas.usp.br:article/172921
network_acronym_str USP-19
network_name_str Clinics
repository_id_str
spelling Benzodiazepine use in Sao Paulo, BrazilPsychiatryPharmacyPsychotropic DrugsHypnotics and SedativesBenzodiazepinesOBJECTIVES: To report the prevalence and factors associated with the use of benzodiazepines in the general population and those with a mental health condition in the metropolitan area of Sa˜o Paulo, Brazil. METHODS: 5,037 individuals from the Sao Paulo Megacity Mental Health Survey data were interviewed using the Composite International Diagnostic Interview, designed to generate DSM-IV diagnoses. Additionally, participants were asked if they had taken any medication in the previous 12 months for the treatment of any mental health condition. RESULTS: The prevalence of benzodiazepine use ranged from 3.6% in the general population to 7.8% among subjects with a mental health condition. Benzodiazepine use was more prevalent in subjects that had been diagnosed with a mood disorder as opposed to an anxiety disorder (14.7% vs. 8.1%, respectively). Subjects that had been diagnosed with a panic disorder (33.7%) or bipolar I/II (23.3%) reported the highest use. Individuals aged X50 years (11.1%), those with two or more disorders (11.2%), those with moderate or severe disorders (10%), and those that used psychiatric services (29.8%) also reported higher use. CONCLUSION: These findings give an overview of the use of benzodiazepines in the general population, which will be useful in the public health domain. Benzodiazepine use was higher in those with a mental health condition, with people that had a mood disorder being the most vulnerable. Furthermore, females and the elderly had high benzodiazepine use, so careful management in these groups is required.Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2020-07-27info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/xmlhttps://www.revistas.usp.br/clinics/article/view/17292110.6061/clinics/2020/e1610Clinics; Vol. 75 (2020); e1610Clinics; v. 75 (2020); e1610Clinics; Vol. 75 (2020); e16101980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/172921/162322https://www.revistas.usp.br/clinics/article/view/172921/162323Copyright (c) 2020 Clinicsinfo:eu-repo/semantics/openAccessCampanha, Angela MariaRavagnani, BeatrizMilhoranc¸a, Igor AndréBernik, Márcio AntoniniViana, Maria CarmenWang, Yuan-PangAndrade, Laura Helena2020-07-27T20:17:27Zoai:revistas.usp.br:article/172921Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2020-07-27T20:17:27Clinics - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Benzodiazepine use in Sao Paulo, Brazil
title Benzodiazepine use in Sao Paulo, Brazil
spellingShingle Benzodiazepine use in Sao Paulo, Brazil
Campanha, Angela Maria
Psychiatry
Pharmacy
Psychotropic Drugs
Hypnotics and Sedatives
Benzodiazepines
title_short Benzodiazepine use in Sao Paulo, Brazil
title_full Benzodiazepine use in Sao Paulo, Brazil
title_fullStr Benzodiazepine use in Sao Paulo, Brazil
title_full_unstemmed Benzodiazepine use in Sao Paulo, Brazil
title_sort Benzodiazepine use in Sao Paulo, Brazil
author Campanha, Angela Maria
author_facet Campanha, Angela Maria
Ravagnani, Beatriz
Milhoranc¸a, Igor André
Bernik, Márcio Antonini
Viana, Maria Carmen
Wang, Yuan-Pang
Andrade, Laura Helena
author_role author
author2 Ravagnani, Beatriz
Milhoranc¸a, Igor André
Bernik, Márcio Antonini
Viana, Maria Carmen
Wang, Yuan-Pang
Andrade, Laura Helena
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Campanha, Angela Maria
Ravagnani, Beatriz
Milhoranc¸a, Igor André
Bernik, Márcio Antonini
Viana, Maria Carmen
Wang, Yuan-Pang
Andrade, Laura Helena
dc.subject.por.fl_str_mv Psychiatry
Pharmacy
Psychotropic Drugs
Hypnotics and Sedatives
Benzodiazepines
topic Psychiatry
Pharmacy
Psychotropic Drugs
Hypnotics and Sedatives
Benzodiazepines
description OBJECTIVES: To report the prevalence and factors associated with the use of benzodiazepines in the general population and those with a mental health condition in the metropolitan area of Sa˜o Paulo, Brazil. METHODS: 5,037 individuals from the Sao Paulo Megacity Mental Health Survey data were interviewed using the Composite International Diagnostic Interview, designed to generate DSM-IV diagnoses. Additionally, participants were asked if they had taken any medication in the previous 12 months for the treatment of any mental health condition. RESULTS: The prevalence of benzodiazepine use ranged from 3.6% in the general population to 7.8% among subjects with a mental health condition. Benzodiazepine use was more prevalent in subjects that had been diagnosed with a mood disorder as opposed to an anxiety disorder (14.7% vs. 8.1%, respectively). Subjects that had been diagnosed with a panic disorder (33.7%) or bipolar I/II (23.3%) reported the highest use. Individuals aged X50 years (11.1%), those with two or more disorders (11.2%), those with moderate or severe disorders (10%), and those that used psychiatric services (29.8%) also reported higher use. CONCLUSION: These findings give an overview of the use of benzodiazepines in the general population, which will be useful in the public health domain. Benzodiazepine use was higher in those with a mental health condition, with people that had a mood disorder being the most vulnerable. Furthermore, females and the elderly had high benzodiazepine use, so careful management in these groups is required.
publishDate 2020
dc.date.none.fl_str_mv 2020-07-27
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/clinics/article/view/172921
10.6061/clinics/2020/e1610
url https://www.revistas.usp.br/clinics/article/view/172921
identifier_str_mv 10.6061/clinics/2020/e1610
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/clinics/article/view/172921/162322
https://www.revistas.usp.br/clinics/article/view/172921/162323
dc.rights.driver.fl_str_mv Copyright (c) 2020 Clinics
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2020 Clinics
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/xml
dc.publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
dc.source.none.fl_str_mv Clinics; Vol. 75 (2020); e1610
Clinics; v. 75 (2020); e1610
Clinics; Vol. 75 (2020); e1610
1980-5322
1807-5932
reponame:Clinics
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Clinics
collection Clinics
repository.name.fl_str_mv Clinics - Universidade de São Paulo (USP)
repository.mail.fl_str_mv ||clinics@hc.fm.usp.br
_version_ 1800222765143293952